By Sam Tobin LONDON (Reuters) – Pfizer and BioNTech asked a London court to revoke rival Moderna’s patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday. Pfizer and its German partner BioNTech sued Moderna at London’s High Court in September 2022, […]
(Reuters) – Moderna said on Thursday it had paused its plans to build a vaccine manufacturing facility in Kenya, following a post-pandemic decline in demand for COVID-19 vaccines. The company had said in 2022 that it would invest about $500 million in the Kenyan facility and supply as many as 500 million doses of its […]
Shares of Moderna (MRNA) are moving up on Tuesday afternoon after the company released positive data for its individualized cancer vaccine tested in combination with Merck’s Keytruda (MRK). The vaccine aims to train patients’ immune systems to recognize and attack specific mutations in cancer cells. Yahoo Finance Anchors Josh Lipton and Julie Hyman break down […]
(Reuters) -Moderna shares rose 8% to a three-month high on Tuesday after the company’s individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of head and neck cancer. The vaccine, designed to train the immune system of patients to recognize and attack specific mutations in cancer […]
(Reuters) -Shares of Moderna fell 4% on Wednesday after a U.S. judge issued an order that strengthened Arbutus’ arguments in a patent infringement lawsuit related to Moderna’s blockbuster COVID-19 vaccines. Roivant’s shares gained 4% in afternoon trading, while its subsidiary Arbutus rose more than 17%. In a so-called “claim construction order”, U.S. District Judge Mitchell […]
A few years ago, both Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) were flying high: from an earnings and share performance perspective. They each sold a leading coronavirus vaccine — and Pfizer sold a COVID treatment too — and these products generated billions of dollars in earnings for the companies. Pfizer and Moderna still sell […]
It’s always possible to come up with a justification for why someone should sell their shares of a stock, but that doesn’t make every justification correct. For a company like Moderna (NASDAQ: MRNA) that just reported some not-so-great news, rushing to quit your position could be a mistake that causes you to miss out down […]
By Patrick Wingrove and Leroy Leo (Reuters) – Moderna on Thursday reported a surprise fourth-quarter profit helped by cost cutting and some deferred payments, and the vaccine maker set out a commercial roadmap for its experimental respiratory syncytial virus (RSV) shot. Moderna posted a profit of $217 million, or 55 cents a share, for the […]
Feb 9 (Reuters) – Shares of Metagenomi Technologies , a genetic medicines company backed by Bayer Healthcare and Moderna, slumped 32% in their Nasdaq debut on Friday. The stock opened for trading at $10.25 compared with the IPO price of $15 per share. The lukewarm debut, which gives Metagenomi a valuation of $384 million, underscores […]
COVID-19 has been especially rough for Pfizer (NYSE: PFE) and Moderna (NASDAQ: MRNA) investors over the last couple of years. Shares of both drugmakers have plunged as the demand for their respective COVID-19 vaccine declined significantly. Problems often present opportunities, though. Pfizer and Moderna just might be rebound candidates in 2024. But which of these […]
Telecom Street Notes By Callum Keown Jan 03, 2024, 7:46 am EST Share Reprints It’s been a busy start to the year on Wall Street with a deluge of stock upgrades and downgrades. Continue reading this article with a Barron’s subscription. View Options
Biotech and Pharma By Emily Dattilo and Josh Nathan-Kazis Updated Jan 02, 2024, 3:24 pm EST / Original Jan 02, 2024, 8:25 am EST Share Reprints Shares of Covid-19 vaccine maker Moderna were on track for their best single-day performance in more than a year, after an analyst at Oppenheimer issued a rare upgrade of […]